Cargando…

Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses

Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoud, Sara H., Khalil, Ahmed A., Abo Shama, Noura M., El Sayed, Marwa F., Soliman, Reem A., Hagag, Naglaa M., Yehia, Nahed, Naguib, Mahmoud M., Arafa, Abdel-Sattar, Ali, Mohamed A., El-Safty, Mounir M., Mostafa, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538193/
https://www.ncbi.nlm.nih.gov/pubmed/37766075
http://dx.doi.org/10.3390/vaccines11091397
_version_ 1785113270515924992
author Mahmoud, Sara H.
Khalil, Ahmed A.
Abo Shama, Noura M.
El Sayed, Marwa F.
Soliman, Reem A.
Hagag, Naglaa M.
Yehia, Nahed
Naguib, Mahmoud M.
Arafa, Abdel-Sattar
Ali, Mohamed A.
El-Safty, Mounir M.
Mostafa, Ahmed
author_facet Mahmoud, Sara H.
Khalil, Ahmed A.
Abo Shama, Noura M.
El Sayed, Marwa F.
Soliman, Reem A.
Hagag, Naglaa M.
Yehia, Nahed
Naguib, Mahmoud M.
Arafa, Abdel-Sattar
Ali, Mohamed A.
El-Safty, Mounir M.
Mostafa, Ahmed
author_sort Mahmoud, Sara H.
collection PubMed
description Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2.
format Online
Article
Text
id pubmed-10538193
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105381932023-09-29 Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses Mahmoud, Sara H. Khalil, Ahmed A. Abo Shama, Noura M. El Sayed, Marwa F. Soliman, Reem A. Hagag, Naglaa M. Yehia, Nahed Naguib, Mahmoud M. Arafa, Abdel-Sattar Ali, Mohamed A. El-Safty, Mounir M. Mostafa, Ahmed Vaccines (Basel) Article Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. MDPI 2023-08-22 /pmc/articles/PMC10538193/ /pubmed/37766075 http://dx.doi.org/10.3390/vaccines11091397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mahmoud, Sara H.
Khalil, Ahmed A.
Abo Shama, Noura M.
El Sayed, Marwa F.
Soliman, Reem A.
Hagag, Naglaa M.
Yehia, Nahed
Naguib, Mahmoud M.
Arafa, Abdel-Sattar
Ali, Mohamed A.
El-Safty, Mounir M.
Mostafa, Ahmed
Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title_full Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title_fullStr Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title_full_unstemmed Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title_short Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
title_sort immunogenicity and cross-protective efficacy induced by an inactivated recombinant avian influenza a/h5n1 (clade 2.3.4.4b) vaccine against co-circulating influenza a/h5nx viruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538193/
https://www.ncbi.nlm.nih.gov/pubmed/37766075
http://dx.doi.org/10.3390/vaccines11091397
work_keys_str_mv AT mahmoudsarah immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT khalilahmeda immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT aboshamanouram immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT elsayedmarwaf immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT solimanreema immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT hagagnaglaam immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT yehianahed immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT naguibmahmoudm immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT arafaabdelsattar immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT alimohameda immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT elsaftymounirm immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses
AT mostafaahmed immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses